Skip to main content

Seres Therapeutics, Inc.

corporate_fare Company Profile

Seres Therapeutics, Inc.

MCRB·NASDAQ·Life Sciences·CIK 0001609809

This company is a clinical-stage firm dedicated to enhancing patient outcomes in medically vulnerable groups by discovering and developing new live biotherapeutic product (LBP) candidates. The company successfully developed and secured approval for VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A. (SPN) and its affiliates, collectively Nestlé Health Science, in September 2024. The company possesses advanced capabilities and platforms, supported by human data sets, to progress a portfolio of products that address diseases by targeting host pathways modulated by microbes in the human body, particularly those associated with mucosal barrier-immune interface targets. Clinical and nonclinical data from its programs support the development of LBPs to prevent and treat a wide range of infections, and to treat inflammatory and immune (I&I) diseases. Its pipeline includes SER-155, SER-603, and SER-147, along with other potential candidates in earlier development. The LBP candidates are bacterial consortia designed for specific pharmacological properties and oral delivery. The company maintains a distinct live biotherapeutics drug discovery and development platform, including good manufacturing practices (GMP) manufacturing capabilities. Pipeline assets, such as SER-155 and SER-603, are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation. The company's knowledge and platforms enable precise consortia design to achieve specific clinical outcomes and offer insights into microbe-associated disease targets. It designs LBP candidates to modulate host function, aiming to increase epithelium integrity, induce immune homeostasis and tolerance, and prevent pathogen colonization and overgrowth in the gastrointestinal (GI) tract.

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for MCRB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for MCRB spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Seres 10-Q: $16.3M Q3 Loss, $17.5M Cash, Going Concern Reaffirmed
  • Seres Posts $16.3M Q3 Loss, Pivots SER-155 Toward irEC Prevention With Cash Through Q1 2027
  • Seres Posts $16.3M Q3 Loss, Cash Lasts Only Through Q1 2027
  • Seres Therapeutics CFO Marella Thorell to Resign Effective November 15, 2026
  • Seres Therapeutics Swings to a $4.6M Q2 Profit on Nestlé Payment, but Going Concern Warning Lingers

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$789K
Net Income
$5.7M
Diluted EPS
$0.64
Op. Cash Flow
$1.12M
Free Cash Flow
$865K
Operating Income
-$93.97M
Cash & Equivalents
$45.77M
Debt / Equity
0.00×
Net Margin
7.22×
Shares Outstanding
9.56M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-103276

Short Interest & Short Volume

4.31 days to cover

FINRA reported short interest of 342,237 shares in MCRB as of the October 30, 2026 settlement, a 9.6% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 31.2% of MCRB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)342,237 shares as of October 30, 2026
Change vs prior period▲ 9.6%
Days to cover4.31 at avg daily volume of 79,475
Daily short volume (FINRA facilities)31.2% of 20,672 shares on November 20, 2026
5-day average short volume57.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for MCRB, detected from its recent SEC filings · based on capital-structure filings through 2026-08-04.

1 recent capital raise

Lease Termination Payment in Stock · No Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$1.25 +0.71% today
52-week range · as of 2026-11-04 $1.25 – $29.98
Market cap
$12.64M
Volume
57.1K (0.7× avg)
3-mo avg 80.2K
Live data · 2026-11-22 12:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MCRB - Latest Insights

MCRB
Nov 04, 2026, 10:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $1.25 info
Change: -$0.6212 (-33%) info
Market Cap: $12.642M info
MCRB
Nov 04, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.25 info
Change: -$0.5412 (-30%) info
Market Cap: $12.642M info
MCRB
Nov 04, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.25 info
Change: -$0.4862 (-28%) info
Market Cap: $12.642M info
MCRB
Oct 26, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.98
Real-time Price: $1.25 info
Change: -$0.7312 (-37%) info
Market Cap: $12.642M info
MCRB
Aug 05, 2026, 10:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.04
Real-time Price: $1.25 info
Change: -$3.79 (-75%) info
Market Cap: $12.642M info
MCRB
Aug 05, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.57
Real-time Price: $1.25 info
Change: -$4.32 (-78%) info
Market Cap: $12.642M info
MCRB
Jul 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.14
Real-time Price: $1.25 info
Change: -$5.89 (-83%) info
Market Cap: $12.642M info
MCRB
Jul 08, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.71
Real-time Price: $1.25 info
Change: -$7.46 (-86%) info
Market Cap: $12.642M info
MCRB
Jul 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.71
Real-time Price: $1.25 info
Change: -$7.46 (-86%) info
Market Cap: $12.642M info
MCRB
Jun 05, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.87
Real-time Price: $1.25 info
Change: -$5.62 (-82%) info
Market Cap: $12.642M info
MCRB
Jun 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.87
Real-time Price: $1.25 info
Change: -$5.62 (-82%) info
Market Cap: $12.642M info
MCRB
May 05, 2026, 10:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.58
Real-time Price: $1.25 info
Change: -$6.33 (-84%) info
Market Cap: $12.642M info
MCRB
May 05, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $1.25 info
Change: -$6.59 (-84%) info
Market Cap: $12.642M info
MCRB
May 04, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.61
Real-time Price: $1.25 info
Change: -$6.36 (-84%) info
Market Cap: $12.642M info
MCRB
Apr 27, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.32
Real-time Price: $1.25 info
Change: -$6.07 (-83%) info
Market Cap: $12.642M info
MCRB
Mar 12, 2026, 10:00 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $8.93
Real-time Price: $1.25 info
Change: -$7.68 (-86%) info
Market Cap: $12.642M info
MCRB
Mar 12, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.93
Real-time Price: $1.25 info
Change: -$7.68 (-86%) info
Market Cap: $12.642M info
MCRB
Mar 12, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.93
Real-time Price: $1.25 info
Change: -$7.68 (-86%) info
Market Cap: $12.642M info
MCRB
Mar 02, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.78
Real-time Price: $1.25 info
Change: -$7.53 (-86%) info
Market Cap: $12.642M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets